BACKGROUND: Many new antitumor drugs have been approved in recent years. Their side-effect profiles are distinct from those of older drugs, and their adverse effects are sometimes highly specific, particularly with respect to the skin. METHODS: This article is based on articles retrieved by a selective search in Medline and the database of the American Society of Clinical Oncology (ASCO), as well as on the authors' personal experience. RESULTS: Cutaneous adverse effects are among the more common adverse effects of new antitumor drugs: they occur in up to 34% of patients receiving multikinase inhibitors, up to 90% of those receiving selective tyrosine kinase inhibitors (such as EGFR or mutant BRAF inhibitors), and up to 68% of those receiving immunotherapeutic agents (such as CTLA4 inhibitors). These adverse effects can be correlated with therapeutic benefit, but they can also be treatment-limiting because of their severity or visibility. CONCLUSION: The recognition and proper management of cutaneous adverse effects is an important part of treatment with new antitumor drugs.
BACKGROUND: Many new antitumor drugs have been approved in recent years. Their side-effect profiles are distinct from those of older drugs, and their adverse effects are sometimes highly specific, particularly with respect to the skin. METHODS: This article is based on articles retrieved by a selective search in Medline and the database of the American Society of Clinical Oncology (ASCO), as well as on the authors' personal experience. RESULTS: Cutaneous adverse effects are among the more common adverse effects of new antitumor drugs: they occur in up to 34% of patients receiving multikinase inhibitors, up to 90% of those receiving selective tyrosine kinase inhibitors (such as EGFR or mutant BRAF inhibitors), and up to 68% of those receiving immunotherapeutic agents (such as CTLA4 inhibitors). These adverse effects can be correlated with therapeutic benefit, but they can also be treatment-limiting because of their severity or visibility. CONCLUSION: The recognition and proper management of cutaneous adverse effects is an important part of treatment with new antitumor drugs.
Authors: Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg Journal: Clin Cancer Res Date: 2007-11-02 Impact factor: 12.531
Authors: Sebastian Hoefert; Martin Grimm; Feraydoon Sharghi; Andreas Geist; Michael Krimmel; Siegmar Reinert Journal: Oral Maxillofac Surg Date: 2014-05-15
Authors: Johannes Wohlrab; Nikola Bangemann; Anke Kleine-Tebbe; Marc Thill; Sherko Kümmel; Eva-Maria Grischke; Rainer Richter; Sophie Seite; Diana Lüftner Journal: Breast Cancer (Dove Med Press) Date: 2014-08-01